Huntington's disease (HD) has been intensely studied for many years. As we enter the miRNA age in molecular biology novel approaches are taking place in the study of HD. HD is a neurodegenerative disease and often involves depression prior to symptom onset. Symptoms include mental disorders as well as psychopathological, motor, and cognitive dysfunction. In HD, there is gliosis and loss of neurons in the brain's caudate nucleus, striatum, and frontal lobes. Dysfunction and loss of neurons involves CAG nucleotide repeats in the Huntingtin gene amino-end [1]. miRNAs can attack or interact with multiple pathways. As an example of the study of miRNAs in HD, it has been shown that the miRNA, miR-22, is associated with protective mechanisms against Huntington's disease (HD). Moreover, miR-22 is antiapoptotic. This miRNA may be anti-neurodegenerative since it shows decreased levels of expression in HD and Alzheimer's disease brain (AD). miR-22 possibly interacts with histone deacetylase 4 (HDAC4), REST corepresor 1 (Rcor1) and regulator of G-protein signaling 2 (Rgs2), three genes implicated in the pathogenesis of HD. Increased expression of miR-22 reduced degeneration of cortical and striatal cultured cells that had been exposed to Htt171-82Q, a fragment of mutated huntingtin. The use of miR-22 also reduced apoptosis of neurons exposed to tumor protein p53-inducible nuclear protein 1 (Tp53inp1) and mitogen-activated protein kinase 14/p38 (MAPK14/p38). In addition, miR-22 targeted Rgs2, HDAC4, and Rcor1 mRNAs [2]. This figure is a continuation of the genes shown in Figure 3 and shows additional levels of interactions among the genes; i.e. many of these are downstream from the first level shown in Figure 3 .
